Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:SRPT News 2 October 2025 - 26 January 2026

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

New York, Jan 26, 2026, 05:31 ET — Premarket Sarepta Therapeutics (SRPT.O) climbed about 6.5% to $22.51 in early Monday action. The stock stayed tight, swinging just between $22.51 and $22.57, with roughly 17,600 shares traded, per Public.com data. (Public) The stock surged 9.65% to $23.17 in after-hours trading Friday, fueled by investor bets ahead of Sarepta’s update on its Duchenne muscular dystrophy gene therapy, RTTNews reported. Sarepta plans to unveil three-year “topline” functional data from Part 1 of EMBARK, its global, randomized, placebo-controlled Phase 3 trial of Elevidys in ambulatory kids aged four to seven at treatment, the report
26 January 2026
·····
Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

New York, Jan 24, 2026, 05:28 (EST) — Market closed. Sarepta Therapeutics Inc shares climbed in after-hours trading Friday following the announcement of a Jan. 26 update on three-year data for its Duchenne gene therapy, Elevidys. The stock had closed down 3% at $21.13 but later traded near $22.20, a roughly 5% gain. (MarketWatch) The timing couldn’t be more critical. Sarepta is working to restore confidence in Elevidys after the FDA slapped on its strongest safety warning and restricted the drug’s use to patients who can still walk. This label change followed reports of deaths from acute liver failure in
24 January 2026
·····
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

New York, Jan 12, 2026, 14:53 EST — Regular session. Sarepta Therapeutics shares dropped roughly 13% to $20.73 in Monday afternoon trading following a disappointing sales forecast for its Duchenne muscular dystrophy gene therapy, Elevidys, in the fourth quarter. This matters because Elevidys has turned into the company’s key swing factor — and a closely watched one at that — for a stock that’s already been tossed around by safety concerns and shifts in treatment protocols over the past year. The timing coincides with the J.P. Morgan Healthcare Conference, where investors usually demand clear guidance and early insights for the
12 January 2026
····
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is back in the spotlight on Tuesday, December 16, 2025—not because the story suddenly got simpler, but because it’s at the intersection of three things the market obsessively prices every day: regulatory risk, clinical evidence, and cash runway. SRPT shares traded around $22 in the U.S. session on Dec. 16, up roughly a couple percent in morning trading. StockAnalysis That price level is a reminder of how dramatically sentiment has reset in 2025: Sarepta’s market capitalization now sits in the low single-digit billions (roughly $2–$3B, depending on intraday moves). StockAnalysis+2Yahoo Finance+2 So what’s “current” as
16 December 2025
·····
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day investing.com. This followed a general uptrend in recent weeks: SRPT is up roughly 16% over the last month marketbeat.com (though still down >80% from early 2025 levels). Trading volume has been moderate (0.6 million on Oct 2 vs. ~5–9M in prior days) investing.com. Over five trading days it gained +14.6% marketbeat.com, reflecting renewed investor interest. By contrast, the stock had sunk to ~$10–12 in mid-2025 amid safety concerns. Year-to-date, SRPT’s performance is dismal: a –82% return in one year marketbeat.com,
2 October 2025
·····

Stock Market Today

AST SpaceMobile stock bounces late Friday as AT&T plays down Amazon Leo threat and a new 2x short ETF hits tape

AST SpaceMobile stock bounces late Friday as AT&T plays down Amazon Leo threat and a new 2x short ETF hits tape

7 February 2026
AST SpaceMobile shares jumped 9.1% to $101.79 Friday after a volatile week, with 15.9 million shares traded. AT&T said it will use Amazon Leo’s satellite network to reach business customers outside its terrestrial footprint but stated this will not affect its partnership with AST. A new 2x short ETF tied to ASTS, ticker ASTN, began trading on Cboe. AST’s next “BlueBird 7” satellite launch is set for late February on Blue Origin’s New Glenn.
Go toTop